Video
Current challenges in the treatment of high-risk non-metastatic RCC
Author(s):
“New regimens should now start to be explored, both…single-agent drugs as well as combination therapies,” says Pavlos Msaouel, MD, PhD.
Video Player is loading.
In this video, Pavlos Msaouel, MD, PhD, discusses challenges that physicians face when treating patient with high-risk non-metastatic renal cell carcinoma, which were highlighted in his presentation, “The future of adjuvant therapy for high-risk non-metastatic RCC,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Msaouel is an assistant professor in the department of genitourinary medical oncology of the division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
